Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A recent collaborative study from the University of Oxford has investigated the potential benefit of a combined therapy approach to prostate cancer treatment, using radiotherapy and vascular targeted photodynamic therapy (VTP), which could lead to first-in-man early phase clinical trials.

Machine used for treatment

Each year in the UK around 48,500 men are diagnosed with prostate cancer, and 11,900 die from this malignancy. The most common radical treatments for prostate cancer are surgical removal of the prostate gland (prostatectomy), or radiotherapy (usually combined with hormone treatment). However, there is a need to improve the overall patient outcomes from radical treatment, as many cases of high-risk prostate cancer recur. Moreover, there is an unmet clinical need to reduce radical treatment side effects.

Vascular targeted photodynamic therapy (VTP) is a novel minimally invasive precision surgery technique that has been developed to focally treat prostate cancer. VTP destroys the vasculature supply of blood to the tumour, thereby providing tumour control. To date, VTP has been investigated in clinical trials as a monotherapy for low-volume, low-risk prostate cancer. Whilst VTP has been combined with other treatments such as hormone therapy in pre-clinical models, to date it has not been investigated alongside external beam radiotherapy to assess the effects of combined treatment on prostate cancer tumour control.

A recent study from Associate Professor Richard Bryant and Professor Freddie Hamdy of the Nuffield Department of Surgical Sciences, alongside collaborators in the Institute of Biomedical Engineering and Department of Oncology, and collaborators from the Weizmann Institute of Science (Israel) and the National Cancer Institute (National Institutes of Health, USA), has investigated the impact of combining VTP with external beam radiotherapy treatment, and the potential improvement to treatment outcomes.

Read the full story on the Nuffield Department of Surgical Sciences website

Similar stories

Oxford vaccine reaches one billion doses released

The University of Oxford’s and our partners AstraZeneca have today announced that one billion doses of the ChAdOx1 nCov-19 coronavirus vaccine have been released, to more than 170 countries, marking a key milestone as part of the University and AstraZeneca’s joint vision to make the available to the world, on a not-for-profit basis for the world during the pandemic, and in perpetuity for low- and middle-income countries.

Research programme tackling COVID-19 variants of concern receives funding boost

A gift from the Red Avenue Foundation will enable the expansion of a major research programme aimed at rapidly identifying and interrogating emerging COVID-19 variants.

Phase I trial begins of new vaccine against the Plague

Researchers at the University of Oxford today launched a Phase 1 trial to test a new vaccine against plague.

New therapeutic targets identified in the treatment of psoriatic arthritis

Researchers identify two inflammatory-driving proteins, osteopontin and CCL2, highly expressed in psoriatic arthritis joints.

Treatment choice for rotator cuff disorders could create efficiency and savings for the NHS

A trial that evaluated the clinical and cost effectiveness of physiotherapy treatments for rotator cuff disorders suggests cost savings can be made while maintaining positive patient outcomes.